Document is current
Any future updates will be listed below
-
Authors
Konta, Tsuneo https://orcid.org/0000-0001-7681-6469
Asahi, Koichi
Tamura, Kouichi https://orcid.org/0000-0002-0660-5372
Tanaka, Fumitaka https://orcid.org/0000-0002-3520-3305
Fukui, Akira https://orcid.org/0000-0002-7383-4159
Nakamura, Yusuke https://orcid.org/0000-0001-8131-9387
Hirose, Junichi https://orcid.org/0009-0006-3916-0759
Ohara, Kenichi https://orcid.org/0000-0003-4513-390X
Shijoh, Yoko https://orcid.org/0000-0001-8175-3845
Carter, Matthew https://orcid.org/0009-0005-6391-1703
Meredith, Kimberley https://orcid.org/0000-0003-3700-5430
Harris, James https://orcid.org/0000-0002-8542-3189
Åkerborg, Örjan https://orcid.org/0000-0003-3003-4271
Kashihara, Naoki https://orcid.org/0000-0002-9487-984X
Yokoo, Takashi https://orcid.org/0000-0003-1838-7998
-
Funding
Funding for this research was provided by:
Bayer Yakuhin
Ministry of Health, Labour and Welfare (JPMH22FD2001)
- License Information
-
More Information
Article History
Received: 4 July 2024
Accepted: 17 November 2024
First Online: 16 December 2024
Declarations
:
: T.K. reports personal fees from Bayer Yakuhin, Daiichi-Sankyo, MSD, Japan Boehringer Ingelheim, Sanwa Kagaku, Dainippon-Sumitomo, Kowa, Kyowa Kirin, Astellas Pharm, AstraZeneca, and Kissei, grants and personal fees from Chugai, Mochida, Tanabe-Mitsubishi Pharm and Novartis, outside the submitted work. K.A. reports payment or honoraria from AstraZeneca, Kyowa-Kirin, Mochida, Bayer, Astellas, Otsuka and Tanabe Mitsubishi, outside the submitted work. K.T. reports grants from AstraZeneca, Ono, Bayer, Kyowa-Kirin, Otsuka, Takeda, and Daiichi-Sankyo, outside the submitted work, payment or honoraria from Novartis, AstraZeneca, Ono, Daiichi-Sankyo, Takeda, Otsuka, Bayer, and Kyowa-Kirin, outside the submitted work. F.T. declares no relevant or material financial interests that relate to the research described in this paper. A.F. declares no relevant or material financial interests that relate to the research described in this paper. Y.N., J.H., K.O., and Y.S. are employees of Bayer Yakuhin Ltd. M.C., K.M., J.Harris, and Ö.Å. are employees of Wickenstones and were contracted as consultants by Bayer for the submitted work. N.K. declares payment or honoraria from Bayer, Ono, Novartis, Boehringer Ingelheim Japan, Astellas, and AstraZeneca, consulting fees and payment or honoraria from Kyowa Kirin and Novo Nordisk, leadership or fiduciary role in Japanese Society of Nephrology and Japan Kidney Association, outside the submitted work. T.Y. declares grants from Zenjinkai, Fuji Yakuhin Co. Ltd., Otsuka Pharmaceutical, Nippon Boehringer Ingelheim Co. Ltd., Kyowa Kirin Co. Ltd., Chugai Pharmaceutical Co. Ltd., Baxter Limited, Teijin Pharma, Daiichi Sankyo Company Limited, Sumitomo Pharma Co. Ltd. (Sumitomo Dainippon Pharma CO. LTD.), Ping An-Shionogi Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Torii Medical Plaza, Eli Lilly Japan K.K., Takeda Pharmaceuticals, Kissei Pharmaceutical Co. Ltd., and Mochida Pharmaceutical Plant Co. Ltd, payment or honoraria from Takeda Pharmaceuticals, Chugai Pharmaceutical Co. Ltd., Sumitomo Pharma Co. Ltd. (Sumitomo Dainippon Pharma Co. Ltd.), Kyowa Kirin Co. Ltd., AstraZeneca K.K., Kissei Pharmaceutical Co. Ltd., Astellas Pharma Inc., Nippon Boehringer Ingelheim Co. Ltd., Bayer Yakuhin Ltd., Torii Medical Plaza, Novo Nordisk Pharma Ltd., Sanofi K.K., and Fuso Pharmaceuticals Industries Ltd.
: Not applicable.
: Not applicable.
